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Original Article

Mometasone or Tiotropium in Mild Asthma
with a Low Sputum Eosinophil Level
S.C. Lazarus, J.A. Krishnan, T.S. King, J.E. Lang, K.V. Blake, R. Covar, N. Lugogo,
S. Wenzel, V.M. Chinchilli, D.T. Mauger, A.-M. Dyer, H.A. Boushey, J.V. Fahy,
P.G. Woodruff, L.B. Bacharier, M.D. Cabana, J.C. Cardet, M. Castro, J. Chmiel,
L. Denlinger, E. DiMango, A.M. Fitzpatrick, D. Gentile, A. Hastie, F. Holguin,
E. Israel, D. Jackson, M. Kraft, C. LaForce, R.F. Lemanske, Jr., F.D. Martinez,
W. Moore, W.J. Morgan, J.N. Moy, R. Myers, S.P. Peters, W. Phipatanakul,
J.A. Pongracic, L. Que, K. Ross, L. Smith, S.J. Szefler, M.E. Wechsler,
and C.A. Sorkness, for the National Heart, Lung, and Blood Institute AsthmaNet*

A BS T R AC T
BACKGROUND

In many patients with mild, persistent asthma, the percentage of eosinophils in sputum is
less than 2% (low eosinophil level). The appropriate treatment for these patients is unknown.
METHODS

In this 42-week, double-blind, crossover trial, we assigned 295 patients who were at least
12 years of age and who had mild, persistent asthma to receive mometasone (an inhaled
glucocorticoid), tiotropium (a long-acting muscarinic antagonist), or placebo. The patients
were categorized according to the sputum eosinophil level (<2% or ≥2%). The primary
outcome was the response to mometasone as compared with placebo and to tiotropium
as compared with placebo among patients with a low sputum eosinophil level who had
a prespecified differential response to one of the trial agents. The response was determined according to a hierarchical composite outcome that incorporated treatment failure,
asthma control days, and the forced expiratory volume in 1 second; a two-sided P value
of less than 0.025 denoted statistical significance. A secondary outcome was a comparison of results in patients with a high sputum eosinophil level and those with a low level.
RESULTS
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A total of 73% of the patients had a low eosinophil level; of these patients, 59% had a
differential response to a trial agent. However, there was no significant difference in the
response to mometasone or tiotropium, as compared with placebo. Among the patients
with a low eosinophil level who had a differential treatment response, 57% (95% confidence interval [CI], 48 to 66) had a better response to mometasone, and 43% (95% CI,
34 to 52) had a better response to placebo (P = 0.14). In contrast 60% (95% CI, 51 to 68)
had a better response to tiotropium, whereas 40% (95% CI, 32 to 49) had a better response to placebo (P = 0.029). Among patients with a high eosinophil level, the response
to mometasone was significantly better than the response to placebo (74% vs. 26%) but
the response to tiotropium was not (57% vs. 43%).
CONCLUSIONS

The majority of patients with mild, persistent asthma had a low sputum eosinophil level
and had no significant difference in their response to either mometasone or tiotropium
as compared with placebo. These data provide equipoise for a clinically directive trial to
compare an inhaled glucocorticoid with other treatments in patients with a low eosinophil level. (Funded by the National Heart, Lung, and Blood Institute; SIENA ClinicalTrials
.gov number, NCT02066298.)
n engl j med 380;21
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sthma is heterogeneous, and many
patients do not have an acceptable response to currently available treatment,
most of which targets eosinophilic inflammation.
In previous studies, investigators found that approximately half of patients with asthma had a
poor response to inhaled glucocorticoids1-3 and
that eosinophilic airway inflammation was not
ubiquitous in the patients.4-7 In contrast to patients who have a percentage of sputum eosinophils of 2% or more, in whom the forced expiratory volume in 1 second (FEV1) increases with
the use of inhaled glucocorticoids, those with a
low eosinophil level (<2%) may not have a response to glucocorticoids.7 Thus, the two subgroups of eosinophil levels may represent two
different phenotypes of asthma with different
needs for therapy.8,9
Guidelines recommend the use of inhaled
glucocorticoids in all patients with persistent
asthma.10,11 Because in approximately 50% of
patients, mild, persistent asthma may not be associated with sputum eosinophilia, it is important to determine prospectively whether these
patients benefit from inhaled glucocorticoids and,
if not, to consider alternative treatments. Since
the risk of monotherapy with long-acting betaagonists (LABAs)12 ruled out their use, we considered tiotropium, a long-acting muscarinic
antagonist (LAMA), as a safe alternative in a
controller medication.13-16 Thus, in the Steroids
in Eosinophil Negative Asthma (SIENA) trial, we
compared an inhaled glucocorticoid (mometasone) and tiotropium with placebo in patients
with mild, persistent asthma, according to the
patients’ sputum eosinophil level at baseline.

Me thods
Patients

We enrolled patients who were at least 12 years
of age and who had received a clinical diagnosis
of asthma and met the guideline criteria of the
National Asthma Education and Prevention Program for step 2 asthma treatment.10,11 The asthma
diagnosis was confirmed by either an increase of
200 ml in the FEV1 (and representing an increase
of ≥12%) after the administration of albuterol or
a 20% reduction in FEV1 in response to a provocative concentration of inhaled methacholine
(PC20) of 16 mg per milliliter or less. Patients
were excluded if they had received an inhaled
2010
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Figure 1 (facing page). Trial Design and Randomization.
Panel A shows the trial design calling for the enrollment
of patients who met the guideline criteria for step 2
asthma treatment in a 6-week single-blind placebo runin period for characterization of asthma. Sputum induc
tion (SI) was performed up to three times to guarantee
the collection of two acceptable samples. At the end of
the run-in period, patients who continued to meet the
criteria for step 2 treatment and who met the adherence
criteria for medication use and diary completion were
stratified according to the sputum eosinophil (EOS)
level (<2% or ≥2%) and were randomly assigned to
receive one of three blinded regimens in random se
quence for 12 weeks each. Throughout the trial, patients
used an electronic diary to record asthma symptoms,
nighttime awakenings, and morning and evening peak
expiratory flow. Inhaler use was tracked by device dose
counters. Panel B shows the number of patients who
enrolled in the trial, underwent randomization, and
completed the trial. A sputum sample was deemed to be
unacceptable if it contained more than 80% squamous
cells, if there was an inadequate sputum volume, or if
the patient was unable to continue the induction pro
cedure for at least 4 minutes. After 74 patients were
categorized as being in the high-eosinophil stratum,
subsequent patients with a high eosinophil level did
not undergo randomization.

glucocorticoid within 3 weeks, an oral glucocorticoid within 6 weeks, or omalizumab within
3 months; had a respiratory infection within
4 weeks; had any cigarette use during the previous 12 months or a lifetime use of more than
10 pack-years; had a history of life-threatening
asthma; or had an FEV1 of less than 70% of the
predicted value.
Trial Design

We conducted this randomized, double-blind,
placebo-controlled crossover trial at 24 sites in the
United States that are included in the AsthmaNet
consortium of the National Heart, Lung, and
Blood Institute (NHLBI). The protocol, modifications, and statistical analysis plan are available with the full text of this article at NEJM.org.
Adult patients provided written informed consent; for adolescents, parents or legal guardians
provided written informed consent, and adolescents provided assent.
The patients were enrolled in a 6-week, singleblind placebo run-in period for characterization
of their asthma, sputum eosinophilia, and asthma control and to establish adherence of more
than 75% to the trial agent and daily completion
of an electronic diary (Fig. 1A). Spirometric meanejm.org

May 23, 2019

The New England Journal of Medicine
Downloaded from nejm.org at Washington University in St. Louis Becker Library on June 24, 2019. For personal use only. No other uses without permission.
Copyright © 2019 Massachusetts Medical Society. All rights reserved.

Mometasone or Tiotropium in Mild Asthma

A Trial Design
In any order
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Active mometasone
Placebo tiotropium
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Active tiotropium

Placebo mometasone
Placebo tiotropium

Active mometasone
Placebo tiotropium

Placebo mometasone
Active tiotropium

Placebo mometasone
Placebo tiotropium

Period 1

Period 2

Period 3

Run-in
Single-blind
placebo
High
EOS

0
3
6
(SI,
(SI,
(SI,
visit 1) visit 2) visit 3)

12
(visit 4)

18
(visit 5)

24
(visit 6)

30
(visit 7)

36
(visit 8)

42
(visit 9)

Week

B Enrollment and Randomization
564 Patients entered run-in period

269 Were excluded
44 Withdrew consent
84 Had unacceptable sputum sample
40 Had EOS ≥2% after stratum closed
24 Had asthma exacerbation or 2 treatment
failures
27 Were lost to follow-up
29 Were nonadherent
6 Had adverse event
15 Had other reasons

295 Underwent randomization

221 Were assigned to low-EOS stratum

74 Were assigned to high-EOS stratum

204 (92%) Completed period 1

71 (96%) Completed period 1

184 (83%) Completed period 2

67 (91%) Completed period 2

176 (80%) Completed period 3

65 (88%) Completed period 3

26 Withdrew consent
14 Were lost to follow-up
5 Had other reasons

9 Withdrew consent

surements were performed and albuterol revers- methacholine bronchoprovocation before the secibility was assessed at the first visit. If reversi ond visit. Sputum induction was performed up
bility was not shown, the patients returned for to three times during the run-in period to obtain
n engl j med 380;21
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two acceptable samples for cell counts on the
basis of a validated protocol.3,12,17,18
The patients were classified as having a high
eosinophil level if eosinophils made up at least
2% of at least one sputum sample. Patients with
two sputum samples that contained less than
2% of eosinophils were designated as having a
low eosinophil level. We obtained samples of
serum periostin, blood eosinophils, and exhaled
nitric oxide each time sputum induction was performed. The patients entered the double-blind
crossover phase at the end of the run-in period
if they continued to meet the criteria for step 2
treatment, had provided two acceptable sputum
samples, met the adherence criteria for medication use and diary completion, did not have two
or more episodes of treatment failure or one
asthma exacerbation (Sections 4.1 and 4.2 in the
Supplementary Appendix, available at NEJM.org),
and the severity of asthma had not escalated to
meet the criteria for step 3 treatment.
Protocol Revision

of

m e dic i n e

Asmanex HFA [Merck]), once-daily tiotropium
(at a dose of 5 μg with Spiriva Respimat [Boehringer Ingelheim]), or twice-daily placebo. (Details regarding the assignment of the inhaler
device are provided in Section 6.1 in the Supplementary Appendix.) Trial-group assignments were
masked by the use of matched masked inhalers
that delivered placebo. To account for transitioning from one trial group to another, diary data
from the initial 4 weeks of each 12-week treatment period were omitted from the analysis.
Treatment failure and asthma exacerbations that
occurred during this 4-week transition period
were counted as events assigned to the ongoing
trial agent.
Evaluation Instruments

All the patients used an electronic diary (Spirotel,
Medical International Research) to record symptoms, medication use, nighttime awakenings,
and morning and evening peak expiratory flow.
The patients were seen every 6 weeks and assessed by phone at the 3-week point between
visits. We used standard AsthmaNet procedures
to assess asthma characteristics.20,21 In addition,
we administered the Asthma Control Test (in
which scores range from 5 [uncontrolled] to 25
[well controlled], with a minimally important
difference of 3)22 and the Asthma Bother Profile
(in which scores range from 0 [minimum effect]
to 75 [maximum effect])23 at every visit. During
visits 3, 5, 7, and 9, we administered the Asthma
Symptom Utility Index (which ranges from 0
[worse symptoms] to 1 [fewer symptoms], with
a minimally important difference of 0.09),24 the
Asthma-Specific Work Productivity and Activities
Impairment Questionnaire (with results expressed
as an impairment percentage),25 and the Sinonasal
Questionnaire (which evaluates the frequency of
nasal symptoms on a scale from 0 [never] to 3
[daily])26 (Table S3 in the Supplementary Appendix).

We anticipated that approximately 50% of the
recruited patients would have a low eosinophil
level.7,8 However, after 112 patients had undergone randomization, we found that 76% of these
patients who first enrolled in the trial had a low
eosinophil level. Thus, we revised the order of
our trial objectives to focus the primary outcome
on a comparison between an inhaled glucocorticoid and placebo and between a LAMA and
placebo among the patients with a low eosinophil level. Comparisons of treatments in the higheosinophil stratum and between the two eosinophil strata became secondary objectives and were
included as an important positive control but not
for outcome comparisons. This change in the
priority of trial objectives occurred while all
outcome data were masked and before the completion of enrollment and analysis of the trial
results. The revision was approved by the steering
committee, by the NHLBI, and by the NHLBI- Safety Assessments
appointed data and safety monitoring board.19
Safety criteria were defined to ensure that the
patients whose asthma control worsened received
Trial Regimens
additional treatment early, before the developWe assigned patients in the two eosinophil ment of an exacerbation. Treatment failure was
strata to a three-treatment, crossover trial for a defined and addressed as described previously
total of 36 weeks of randomized treatment. Dur- (Section 4.1 in the Supplementary Appendix).27
ing each 12-week period, the patients received Patients who met the criteria for treatment failtwice-daily mometasone (at a dose of 220 μg ure received an open-label, high-dose inhaled
with the Asmanex Twisthaler or 200 μg with the glucocorticoid (mometasone at a dose of 440 μg
2012
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twice daily for 10 days) in addition to the doubleblind trial agent. When necessary, the treatment
period was extended so that at least 3 weeks
elapsed between treatment with a high-dose inhaled glucocorticoid and crossover to the next
trial period or trial completion. Patients who
had two or more treatment failures or an asthma
exacerbation during one treatment period were
crossed over to the next treatment period or
completed their final visit.
Outcome Measures

The primary outcome was the response to momet
asone as compared with placebo and to tiotropium as compared with placebo among patients
with a low eosinophil level who had a prespecified differential response to a trial agent. The
response was determined according to a hierarchical composite outcome of asthma control that
incorporated treatment failure, annualized number of asthma control days (defined as the number
of days without the rescue use of albuterol, the
use of a concomitant asthma medication, symptoms, urgent care visits, or peak expiratory flow
at <80% of the baseline value), and FEV1 on the
basis of prespecified threshold criteria. We assessed the differential response for the comparisons between both mometasone and tiotropium with placebo.
The patients were defined as having a differential response if no treatment failures occurred
in one period and at least one failure occurred in
another trial period, if the number of annualized
asthma control days was at least 31 days higher
than that in another trial period, or if the FEV1
at the end of the period was at least 5% higher
than that in another trial period. If one trial
agent (either of the active drugs or placebo) was
better than the other with respect to the threshold for treatment failure, we ignored the number
of asthma control days and FEV1. If there was no
difference for treatment failure, and the threshold for the number of asthma control days was
met, we ignored the FEV1. If there was no difference with respect to either treatment failure or
the number of asthma control days, we considered the FEV1 in the analysis. A patient was
considered to have no differential response with
respect to a given comparison if none of the
thresholds were met.
Although we used a combination of all three
hierarchical measures as a composite primary
n engl j med 380;21

outcome, each individual measure was considered separately as a secondary outcome. The
secondary outcomes and prespecified exploratory
outcomes are described in Sections 5.1 and 5.2
in the Supplementary Appendix.
Trial Oversight

The trial was funded by the NHLBI and approved
by the AsthmaNet steering committee, an NHLBIappointed protocol review committee, and a data
and safety monitoring board. Mometasone and
mometasone placebo were donated by Merck,
tiotropium and tiotropium placebo by Boehringer
Ingelheim, and albuterol by Teva. These companies did not play a role in the design of the trial,
in the collection or interpretation of the data, or
in the preparation of the manuscript. Each of the
companies received a copy of the manuscript at
the time that it was submitted for publication.
The authors were responsible for the trial
design, data collection, data interpretation and
analysis, manuscript preparation, and decision
to submit the manuscript for publication. The
authors vouch for the accuracy and completeness
of the data, for the accuracy of the analyses, and
for the fidelity of the trial to the protocol.
Statistical Analysis

The primary research questions were whether an
inhaled glucocorticoid (mometasone) or a LAMA
(tiotropium) was superior to placebo among patients with a low eosinophil level who had a
differential response. We determined that a sample of 262 patients in this stratum would provide
a power of 90% at a two-sided significance of
0.025 (Bonferroni correction) to detect a difference in probabilities of 0.20 while allowing for a
15% withdrawal rate and a 30% rate of no differential response. With the approval of the data
and safety monitoring board, we closed enrollment at 221 patients in the low-eosinophil stratum, which provided a power of just under 85%.19
To evaluate each null hypothesis, we applied
two-sided, exact binomial tests at the 0.025 significance level to data from patients who had a
differential response, according to the hierarchical composite outcome. To assess potential effects of the trial period and seasonal factors,
we performed a sensitivity analysis by applying
logistic-regression models to data from patients
who had a differential response, with covariates
to adjust for differences between trial periods,
nejm.org
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seasons of enrollment, and delivery device for
mometasone (dry powder vs. metered-dose inhaler) (see Section 6.1 in the Supplementary
Appendix).
Prespecified secondary analyses with the primary hierarchical composite outcome included
the same analysis performed with data from
patients in the high-eosinophil stratum, a comparison between mometasone and tiotropium
performed in the same manner as described for
the comparison between placebo and mometasone or tiotropium, and an exploratory subgroup
analysis to evaluate the coprimary research
hypotheses in adults only. We created receiveroperating-characteristic (ROC) curves and estimated the area under the curve (AUC) to determine the predictive value of other biomarkers for
sputum eosinophilia or response to treatment.
We used linear mixed-effects models to analyze
secondary outcome measures for questionnaires
and diary data for longitudinal data after adjustment for baseline values, trial period, eosinophil
stratum, and trial group within the eosinophil
stratum, as well as a random effect for clinical site.
All analyses were performed on the intentionto-treat principle in which data were included for
all the patients who had undergone randomization. Patients with missing data were conservatively assumed to have had a similar response to
both mometasone and tiotropium, so these patients were imputed as not having had a differential response for the purpose of the intentionto-treat analysis with the use of single imputation.
A tipping-point analysis was performed to evaluate the effect of various assumptions applied to
patients with missing outcome data (see Section
6.2 in the Supplementary Appendix).

R e sult s
Patients

The trial was conducted from July 2014 through
March 2018. Of the 564 patients who were enrolled in the run-in period, two acceptable sputum samples were available for 366 patients. Of
these samples, 268 (73%) were classified as having a low eosinophil level and 98 (27%) as having
a high eosinophil level. Of the remaining patients, 109 provided one acceptable sputum sample, and 89 provided no acceptable samples. Of
the 366 patients with two acceptable sputum
2014

n engl j med 380;21

of

m e dic i n e

samples, 295 underwent randomization: 221 to
the low-eosinophil subgroup and 74 to the higheosinophil subgroup (Table 1 and Fig. 1B, and Tables S1 and S2 in the Supplementary Appendix).
A total of 58 patients (20%) were between the
ages of 12 and 18 years; of these patients, 40
(69%) had a low eosinophil level. Among the 221
patients with a low eosinophil level, those who
completed at least two trial periods and provided
data for each comparison in the primary analysis
included 176 (80%) for the comparison between
mometasone and placebo and 181 (82%) for the
comparison between tiotropium and placebo,
which permitted the assessment of a differential
response. Among the 74 patients with a high
eosinophil level, 67 (91%) completed the analysis
periods for the comparison between mometasone and placebo and 62 (84%) completed the
periods for the comparison between tiotropium
and placebo.
At the time of enrollment, all the patients had
mild asthma (mean baseline FEV1 before bronchodilation, 90 to 93% of the predicted value).
During the 12 months before enrollment, 23%
had had at least one urgent care visit for asthma
and 19% had received an oral glucocorticoid for
asthma.
Adherence

There was no significant difference among the
three trial groups in the rate of adherence to the
blinded medications and to diary completion, as
measured by the electronic devices used for this
purpose. The rates did not vary according to
eosinophil subgroup (Section 7.1 in the Supplementary Appendix).
Differential Response to Trial Agents

A differential response for the comparison between mometasone and placebo was observed in
130 of 221 patients (59%) with a low eosinophil
level: 34% had better asthma control while receiving mometasone, 25% had better control while
receiving placebo, 21% showed no between-group
difference, and 20% with missing data were
imputed as having no between-group difference.
For the comparison between tiotropium and
placebo, 36% had better control while receiving
tiotropium, 24% had better control while receiving
placebo, 22% showed no between-group difference, and 18% with missing data were imputed
as having no between-group difference (Fig. 2A).
nejm.org
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Table 1. Characteristics of the Patients at Baseline.*
Low Eosinophil Level
(N = 221)

High Eosinophil Level
(N = 74)

31.2±13.8

31.1±14.2

76 (34)

35 (47)

8.0 (3.0–15.0)

7.0 (3.0–14.0)

19.2±10.9

20.0±12.2

One or more asthma episodes requiring emergency care
or unscheduled office visit in previous yr — no. (%)

52 (24)

17 (23)

One or more courses of systemic glucocorticoids in previous yr
— no. (%)

41 (19)

14 (19)

Characteristic
Demographic features
Age — yr
Male sex — no. (%)
Asthma history
Median age at diagnosis (IQR) — yr
Duration of asthma — yr

Clinical and spirometric features
Body-mass index†

29.1±7.8

26.5±5.7

Predicted FEV1 — %

92.7±12.4

89.5±10.8

Ratio of FEV1 to FVC

0.77±0.08

0.75±0.08

Geometric mean PC20 (±CV) — mg/ml‡

2.42±1.28

1.24±1.27

9.6±7.1

12.7±8.5

21.5 (14.0–35.5)

55.5 (35.0–81.0)

2.6 (1.1–4.0)

4.8 (3.9–7.0)

Median periostin level (IQR) — ng/ml

51.7 (43.3–63.6)

56.3 (49.3–75.2)

Median score on Asthma Control Test (IQR)§

21.0 (20.0–23.0)

21.0 (19.0–23.0)

Bronchodilator response (4 puffs) — % change
Median fraction of exhaled nitric oxide (IQR) — ppb
Median blood eosinophil level (IQR) — %

Patients with eczema or atopic dermatitis — no. (%)
Patients with ≥1 positive allergen test — no./total no. (%)

67 (30)

27 (36)

172/216 (80)

70/72 (97)

*	Plus–minus values are means ±SD unless otherwise noted. CV denotes coefficient of variation, FEV1 forced expiratory
volume in 1 second, FVC forced vital capacity, and IQR interquartile range.
†	The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡	PC20 denotes the provocative concentration of inhaled methacholine that results in a 20% reduction in the FEV1.
§	The score on the Asthma Control Test ranges from 5 (uncontrolled) to 25 (well controlled), with a minimally important
difference of 3.

Primary Analysis

Among the patients with a low eosinophil level
who had a differential response, there was no
significant difference between the percentage
who had a better response to mometasone (57%;
95% confidence interval [CI], 48 to 66) and
those who had a better response to placebo
(43%; 95% CI, 34 to 52; P = 0.14); there was also
no significant difference in the percentage who
had a better response to tiotropium (60%; 95%
CI, 51 to 68) and those who had a better response
to placebo (40%; 95% CI, 32 to 49; P = 0.029)
(Fig. 2B). These conclusions did not change with
sensitivity analyses that included adjustment for
differences in the trial period, season of enrollment, and mometasone delivery device. However,
our conclusions were not robust to assumptions
n engl j med 380;21

regarding missing data, since the results for the
comparison between tiotropium and placebo
would have been different under the missing-atrandom assumption. Although the results of the
comparison between mometasone and placebo
were the same under the missing-at-random assumption, a tipping-point analysis showed that
the results changed if we assumed that patients
with missing data were twice as likely to have
had a better response to mometasone than to
placebo (Section 6.2 in the Supplementary Appendix).
Secondary Analyses

Among the patients with a high eosinophil level
who had a differential response, 74% (95% CI,
60 to 86) had a better response to mometasone
nejm.org

May 23, 2019

2015

The New England Journal of Medicine
Downloaded from nejm.org at Washington University in St. Louis Becker Library on June 24, 2019. For personal use only. No other uses without permission.
Copyright © 2019 Massachusetts Medical Society. All rights reserved.

The

n e w e ng l a n d j o u r na l

A Differential Response to Three Trial Agents
Mometasone vs. Placebo
Mometasone or
placebo better
Neither better

Tiotropium vs. Placebo
Tiotropium or
placebo better
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and 26% (95% CI, 14 to 40) had a better response to placebo; the corresponding better responses were 57% (95% CI, 41 to 72) to tiotropium and 43% (95% CI, 28 to 59) to placebo
(Fig. S1 in the Supplementary Appendix). The
responses among the patients in the two eosinophil strata regarding the individual components
of the hierarchical composite outcome are shown
in Figures S2 and S3 in the Supplementary Appendix. In the two strata, the composite outcome was driven by increases in the FEV1.
Among the patients who had a differential response and who had a better response to mometasone than to tiotropium, there was no significant
difference between the low-eosinophil stratum
(48% vs. 52%) and the high-eosinophil stratum
(55% vs. 45%) (Fig. S4 in the Supplementary
Appendix).

P=0.14

Exploratory Analyses in Adults
Tiotropium

100

80

60

40

20

Placebo

0

20

P=0.029

40

60
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Figure 2. Pairwise Comparisons of Active Treatments and Placebo in the
Low-Eosinophil Stratum.
In this trial, the primary outcome was the response to mometasone as
compared with placebo and to tiotropium as compared with placebo
among patients with a low sputum eosinophil level (<2%) who had a pre
specified differential response to the trial agents. The response was deter
mined according to a hierarchical composite outcome that incorporated
treatment failure, asthma control days, and the forced expiratory volume in
1 second. Panel A shows the prespecified differential response to treat
ment with mometasone as compared with placebo and with tiotropium as
compared with placebo. The patients were considered to have had a differ
ential response if the response during at least one trial period was ranked
better than the response during another trial period. In the comparison be
tween mometasone and placebo, 34% of the patients had better asthma
control while receiving mometasone, 25% had better control while receiv
ing placebo, 21% showed no betweengroup difference, and 20% with
missing data were imputed as having no betweengroup difference. In the
comparison between tiotropium and placebo, 36% had better control while
receiving tiotropium, 24% had better control while receiving placebo, 22%
showed no betweengroup difference, and 18% with missing data were im
puted as having no betweengroup difference. Panel B shows the results of
a statistical comparison of the primary outcome among the patients who
had a differential response to the trial agents, with a twosided P value of
less than 0.025 indicating statistical significance. There was no significant
betweengroup difference in the percentage of patients who had a better
response to mometasone than to placebo (57% vs. 43%, P = 0.14) or in the
percentage who had a better response to tiotropium than to placebo (60%
vs. 40%, P = 0.029). The I bars denote the 95% confidence interval.
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Among adults in the low-eosinophil stratum who
had a differential response, 59% (95% CI, 49 to
69) had a better response to mometasone and
41% (95% CI, 31 to 51) had a better response to
placebo; the corresponding percentages were
62% (95% CI, 52 to 71) for tiotropium and 38%
(95% CI, 29 to 48) for placebo. Among adults in
the high-eosinophil stratum who had a differential response, 78% (95% CI, 62 to 90) had a better response to mometasone and 22% (95% CI,
10 to 38) had a better response to placebo; the
corresponding percentages were 54% (95% CI,
37 to 71) for tiotropium and 46% (95% CI, 29 to
63) for placebo (Fig. S5 in the Supplementary
Appendix).
We examined blood eosinophil levels and the
fraction of exhaled nitric oxide as surrogates for
the sputum eosinophil level by performing the
two measurements whenever sputum samples
were obtained. ROC curves showed that the
blood eosinophil level was a “fair” predictor of a
sputum eosinophil level of less than 2% and the
fraction of exhaled nitric oxide was a “good”
predictor,28 with AUCs of 0.77 and 0.80, respectively. The blood eosinophil level and the fraction of exhaled nitric oxide each predicted response to mometasone (AUC, 0.63) but not to
tiotropium (AUC, 0.48 and 0.54, respectively)
(Figs. S6 through S8 in the Supplementary Appendix).
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Other Measures of Control

In the patients with a high eosinophil level,
scores on the Asthma Control Test and Asthma
Symptom Utility Index were better among those
who received mometasone than among those who
received either tiotropium or placebo. The results for these and other secondary and exploratory outcomes — including findings on questionnaires, peak expiratory flow, and nocturnal
awakenings — are listed in Table S3 in the
Supplementary Appendix.
Adverse Events

There were few adverse events, asthma exacerbations, or treatment failures among the patients.
There was no significant difference in adverse
events between the high-eosinophil stratum and
the low-eosinophil stratum or between the two
active treatment groups (Tables S4 and S5 in the
Supplementary Appendix).

Discussion
Several key findings emerged from our trial of
mometasone and tiotropium involving patients
with mild, persistent asthma who were stratified
according to sputum eosinophil level. Nearly three
quarters of the patients who underwent screening (and who represented broad geographic and
economic distribution within the United States)
were identified as having a low eosinophil level,
a percentage that is much greater than has been
reported in this population previously.7
Although the patients had mild asthma, they
had sufficient symptoms (on >2 days per week,
>2 nights per month, or albuterol rescue on >2 days
per week) to meet the criteria for step 2 treatment (a daily inhaled glucocorticoid), according
to the guidelines of the National Asthma Education and Prevention Program. A substantial percentage of these patients were at risk for a loss
of asthma control. Sputum eosinophilia has been
shown to predict the response to glucocorticoid
therapy,6,7,29 and patients with a low sputum
eosinophil level or a low level of type 2 airway
inflammation do not have a favorable response
to glucocorticoids.7,9 This finding suggests that
standard treatment with mometasone may not
be effective in this population, and we examined
that hypothesis prospectively in this trial.

n engl j med 380;21

The trial was designed to examine two primary comparisons among the patients in the
low-eosinophil stratum: the differential response
to mometasone and to tiotropium, as compared
with placebo, for three measures of asthma control that incorporated treatment failure, asthma
control days, and FEV1, with the use of prespecified threshold criteria. Nearly 60% of the
patients in the low-eosinophil stratum had a
differential response to one of the three trial
agents, but the percentage who had a better response to either active drug was not significantly
greater than the percentage who had a better
response to placebo. In contrast, in a secondary
analysis in the high-eosinophil stratum, the response to mometasone was clearly superior to
the response to placebo.
We enrolled adolescents together with adults
because the treatment guidelines include adolescents in their recommendations. However, we
prespecified separate exploratory analyses in
the adult group and the adolescent group. When
we reanalyzed the primary outcomes among the
adults in the low-eosinophil stratum, a larger
percentage had a better response to tiotropium
than to placebo. Among the 58 patients in the
adolescent group, 40 (69%) had a low eosinophil
level. However, the numbers of adolescent patients
in the two eosinophil strata are too small to allow
for meaningful statistical comparisons.
The use of inhaled glucocorticoids is recommended for nearly all patients with persistent
asthma according to the belief that airway inflammation is ubiquitous in asthma and, if untreated, leads to airway remodeling.30,31 However,
remodeling is far less common than once thought,
and patients with a low level of type 2 airway
inflammation do not have a favorable response to
inhaled glucocorticoids. Our results extend these
observations to a relatively large group of wellcharacterized patients with mild asthma who
have a persistent sputum eosinophil level of less
than 2%. In our trial, sputum eosinophilia was
assigned on the basis of two induced sputum
samples obtained approximately 3 weeks apart,
rather than after a single determination, to minimize the potential of misclassification owing to
variability over time.
Our results raise the question of whether
treatment guidelines should be reevaluated for
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patients with mild, persistent asthma for whom
evidence of type 2 inflammation is lacking.
Among such patients, adherence to prescribed
regimens is often lacking because they tend to
stop using inhaled glucocorticoids when they
feel well, they have concern about potential adverse effects, or they perceive that the treatment
is ineffective. Although our data for patients in
the low-eosinophil stratum do not support current treatment recommendations, the appropriate
controller treatment for these patients remains
to be determined.
In our trial, 73% of the patients with mild,
persistent asthma who underwent screening had
a sputum eosinophil level of less than 2%; in
67% of these patients, the response to placebo
was either as good as or better than the response to mometasone (Fig. S9 in the Supplementary Appendix). The need for a change in
treatment strategy is further highlighted by a
growing body of literature suggesting that mild,
persistent asthma can be managed safely without the daily use of inhaled glucocorticoids and

of

m e dic i n e

by data showing that patients with a low eosinophil level may not have a favorable response to
inhaled glucocorticoids. Among patients with a
low eosinophil level, the daily use of inhaled
glucocorticoids may increase the risk of side effects and the costs of maintenance treatment,
with minimal clinical benefit. Our findings provide clinical equipoise for a larger and longer
study to compare inhaled glucocorticoids with
other treatments for the large number of patients
with mild or moderate asthma. Biomarkers that
have been used to guide treatment mainly in
severe or refractory asthma1-7,9,32,33 may provide
valuable direction in future trials to identify
patients who are most likely to have a response
to inhaled glucocorticoids or to an alternative
therapy.
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